Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Candel Therapeutics Inc (NASDAQ: CADL) was $7.02 for the day, up 0.29% from the previous closing price of $7.0. In other words, the price has increased by $0.29 from its previous closing price. On the day, 0.6 million shares were traded. CADL stock price reached its highest trading level at $7.04 during the session, while it also had its lowest trading level at $6.735.
Ratios:
Our analysis of CADL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.64 and its Current Ratio is at 4.64. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.02.
On February 20, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $25.
On February 19, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $20.Canaccord Genuity initiated its Buy rating on February 19, 2025, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 30 ’25 when Nichols William Garrett sold 781 shares for $5.04 per share. The transaction valued at 3,936 led to the insider holds 52,493 shares of the business.
WILLIAM GARRETT NICHOLS bought 3,593 shares of CADL for $17,606 on Jun 30 ’25. On Mar 18 ’25, another insider, Nichols William Garrett, who serves as the Chief Medical Officer of the company, sold 45,316 shares for $8.76 each. As a result, the insider received 396,995 and left with 52,493 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CADL now has a Market Capitalization of 351720960 and an Enterprise Value of 270468800.
Stock Price History:
The Beta on a monthly basis for CADL is -0.85, which has changed by 0.13776338 over the last 52 weeks, in comparison to a change of 0.16932249 over the same period for the S&P500. Over the past 52 weeks, CADL has reached a high of $14.60, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is 24.24%, while the 200-Day Moving Average is calculated to be 10.47%.
Shares Statistics:
CADL traded an average of 980.95K shares per day over the past three months and 1057370 shares per day over the past ten days. A total of 49.25M shares are outstanding, with a floating share count of 36.70M. Insiders hold about 31.18% of the company’s shares, while institutions hold 36.21% stake in the company. Shares short for CADL as of 1752537600 were 6555372 with a Short Ratio of 6.68, compared to 1749772800 on 6259547. Therefore, it implies a Short% of Shares Outstanding of 6555372 and a Short% of Float of 16.950001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Candel Therapeutics Inc (CADL) is currently being evaluated by 2 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.12 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.53 and -$0.77 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.62, with 1.0 analysts recommending between -$0.62 and -$0.62.
